Identification of Orch3, a Locus Controlling Dominant Resistance to Autoimmune Orchitis, as Kinesin Family Member 1C

Roxana del Rio¹, Ryan D. McAllister², Nathan D. Meeker³, Emma H. Wall¹, Jeffrey P. Bond⁴, Vasileios C. Kyttaris⁵, George C. Tsokos⁵, Kenneth S. K. Tung⁶, Cory Teuscher¹,⁷*

¹Department of Medicine/Immunobiology Program, University of Vermont, Burlington, Vermont, United States of America, ²Department of Microbiology, University of Illinois, Urbana-Champaign, Illinois, United States of America, ³Mountain States Tumor Institute, Boise, Idaho, United States of America, ⁴Vermont Genetics Network Bioinformatics Core, University of Vermont, Burlington, Vermont, United States of America, ⁵Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, ⁶Department of Pathology and Beine B. Carter Center of Immunology, University of Virginia, Charlottesville, Virginia, United States of America, ⁷Department of Pathology, University of Vermont, Burlington, Vermont, United States of America

Abstract

Experimental autoimmune orchitis (EAO), the principal model of non-infectious testicular inflammatory disease, can be induced in susceptible mouse strains by immunization with autologous testicular homogenate and appropriate adjuvants. As previously established, the genome of DBA/2J mice encodes genes that are capable of conferring dominant resistance to EAO, while the genome of BALB/cByJ mice does not and are therefore susceptible to EAO. In a genome scan, we previously identified Orch3 as the major quantitative trait locus controlling dominant resistance to EAO and mapped it to chromosome 11. Here, by utilizing a forward genetic approach, we identified kinesin family member 1C (Kif1c) as a positional candidate for Orch3 and, using a transgenic approach, demonstrated that Kif1c is Orch3. Mechanistically, we showed that the resistant Kif1cD2 allele leads to a reduced antigen-specific T cell proliferative response as a consequence of decreased MHC class II expression by antigen presenting cells, and that the L578→P578 and S1027→P1027 polymorphisms distinguishing the BALB/cByJ and DBA/2J alleles, respectively, can play a role in transcriptional regulation. These findings may provide mechanistic insight into how polymorphism in other kinesins such as KIF21B and KIF5A influence susceptibility and resistance to human autoimmune diseases.

Introduction

Experimental autoimmune orchitis (EAO) is a model of idiopathic male infertility mediated by autoreactive T cells [1,2]. It can be induced in mice by active immunization with mouse testicular homogenate (TH) emulsified in complete Freund’s adjuvant (CFA) and Bordetella pertussis toxin (PTX) [3]. In genetically susceptible mice, the inflammatory lesions comprised of monocytes, macrophages, lymphocytes, neutrophils, and eosinophils are mainly found in the seminiferous tubules of the testes in association with aspermatogenesis [3]. We previously have shown that MHC class II restricted CD4⁺ T cells are the primary effectors in autoimmune orchitis [4,5]. However, recent evidence suggests the involvement of CD8⁺ T cells during the onset and maintenance of chronic inflammation [6,7].

Various strains of inbred mice respond differently to EAO induction, indicating that susceptibility is genetically controlled. Previously, it was shown that BALB/cByJ (CByJ) mice are highly susceptible to EAO [8] whereas DBA/2J (D2) and (CByJ×D2/F1 hybrids (CD2F1) are resistant [3,9]. This demonstrates that resistance to EAO is inherited as a dominant phenotype in this strain combination. Additionally, resistance can be adoptively transferred to CByJ mice with CD2F1 primed splenocytes [10]. Therefore, the factors that regulate EAO resistance appear to be governed by an immune-mediated dominant negative mechanism.

Genome exclusion mapping was utilized to map the immunosuppressive genes regulating dominant resistance to EAO [10] with significant linkages to multiple loci residing on chromosomes (Chr) 1 and 11 [10]. Of these, Orch3 on Chr11 displayed the most significant linkage and accounted for the majority of disease resistance seen in D2 mice.

In this study, congenic mapping was employed to restrict Orch3 to a ~1.3 Mb interval that identified Kif1c (kinesin family member 1c) as a positional candidate. By generating CByJ.CD11B-Kif1cD2 transgenic (Tg) mice, we demonstrated that Kif1c underlies Orch3. Mechanistically, we showed that the resistant Kif1cD2 allele leads to reduced antigen (Ag)-specific T cell responsiveness as a consequence of decreased MHC class II expression by myeloid cells, and that the L578→P578 and S1027→P1027 polymorphisms distinguishing the CByJ and D2 alleles, respectively, can play a role in regulate gene transcription.
Author Summary

Although the etiology of autoimmunity is not well known, a variety of studies have demonstrated that genetic predisposition is a major contributor to disease susceptibility and resistance. The major histocompatibility complex (MHC) is the primary genetic determinant of autoimmune disease susceptibility with multiple additional interacting loci required. However, the identification and characterization of non-MHC genes has been problematic, since most autoimmune diseases are polygenic with the individual genes exhibiting only partial or minimal penetrance. We previously identified Orch3 (mouse chromosome 11) as the most important immune-suppressive locus controlling dominant resistance to autoimmune orchitis, the principal animal model of non-infectious testicular inflammatory/autoimmune disease. Here, using congenic mapping, we identified kinesin family member 1C (Kif1c) as a positional candidate for Orch3. Furthermore, over-expression of the Kif1c resistant allele in susceptible mice rendered animals autoimmune orchitis resistant, demonstrating that Kif1c is Orch3. We propose that Kif1c plays an immunoregulatory role by controlling the levels of MHC class II in antigen presenting cells and consequently impacting autoreactive orchitogenic T cell responses. These findings are particularly relevant since polymorphism in other kinesins such as Kif21B and Kif5A have been associated with susceptibility and resistance to human autoimmune disease.

Results

Congenic mapping of Orch3

In the genome scan in which Orch3 was identified, D11Mit219, D11Mit118, and D11Mit118 exhibited the most significant linkage [10]. As the first step in the positional-candidate gene cloning of Orch3, we used marker-assisted selection to introgress the Orch3D2 allele onto the susceptible CByJ background. Next, we generated overlapping interval specific recombinant congenic (ISRC) lines (Figure S1 and Figure S2) and studied them in a stepwise fashion for susceptibility and resistance to EAO (Figure 1). Importantly, since resistance to EAO is inherited as a dominant trait in CD2F1 hybrid mice [10], and the pathology indices (PI) between heterozygous and homozygous congenic lines were not significantly different (data not shown), the data were pooled for each line. Control parental CByJ mice were clearly susceptible to EAO, with an average PI of 4.0, whereas D2 and CD2F1 hybrid mice were resistant, with an average PI of 0.1 and 0.8, respectively (Figure 2). C.D2-8 was resistant, with an average PI of 0.1 and 0.8, respectively with an average PI of 4.0, whereas D2 and CD2F1 hybrid mice line. Control parental CByJ mice were clearly susceptible to EAO, significantly different (data not shown), the data were pooled for each line. Next, we generated congenic mapping of Orch3, and studied them in a stepwise fashion with average scores of 0.2, 0.6, 1.3, 1.7, and 4.9, 2.6, 3.7, 3.8, and 4.0, respectively. In contrast, C.D2-Evi2, C.D2-3, C.D2-3.2, C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2c and CByJ mice were also susceptible with average scores of 3.6, 4.9, 2.6, 3.7, 3.8, and 4.0, respectively. In contrast, C.D2-Evi2, C.D2-3, C.D2-3.2, C.D2-3.2a and C.D2-3.2b were also susceptible with average scores of 3.6, 4.9, 2.6, 3.7, 3.8, and 4.0, respectively. In contrast, C.D2-Evi2, C.D2-3, C.D2-3.2, C.D2-3.2a and C.D2-3.2b were all resistant, with an average PI of 0.1 and 0.8, respectively (Figure 2). C.D2-Evi2, C.D2-3, C.D2-3.2a and C.D2-3.2b were all resistant, with an average PI of 0.1 and 0.8, respectively (Figure 2). C.D2-3, C.D2-3.2a and C.D2-3.2b were all resistant, with an average PI of 0.1 and 0.8, respectively (Figure 2). C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that C.D2-3.2a and C.D2-3.2b was not significantly different from that.

These data placed Orch3 within the interval between D11Mit298 (69339966-69340164) and NLR (nucleotide-binding domain and leucine rich repeat containing) family, pyrin domain containing 1A, B, C (Nlpr1ab/c) at 70.9–71.0 Mb (70904699–71098734 bp). Importantly, this excluded transient receptor potential cation channel, subfamily V, member 1 (Trpv1) at 73.0 Mb (73047794–73074744) underlying Idd4.1, a quantitative trait loci (QTL) controlling susceptibility to type 1 diabetes in the NOD mouse and inducible nitric oxide synthase (Nos2i/Nos3i) important in inflammatory diseases including autoimmunity [12,13], as candidate genes for Orch3. Nlpr1ab/c is one of two highly polymorphic positional candidate loci of immunological relevance within the interval, the second gene being kinesin family member 1C (Kif1c). However, Nlpr1a could be excluded as a candidate since it is a pseudogene (www.informatics.jax.org) and Nlpr1a and -b are less likely to be relevant to Orch3 than Kif1c due to discordance between EAO susceptibility and Nlpr1a and -b alleles among CByJ, BALB/c and D2 mice [www.informatics.jax.org] [14].

CByJ.CD11B-Kif1cD2 Tg (Tg-Kif1cD2) mice are resistant to EAO

To confirm that Kif1c was the most likely candidate gene for Orch3 and to definitively exclude Nlpr1ab/c as a positional candidate, we generated overlapping sub-ISRC congenic lines across the C.D2-3.2 interval and studied them for susceptibility to EAO (Figure 3). Statistically significant differences in EAO susceptibility between C.D2-3.2, C.D2-3.2c and CByJ mice were observed (Figure 3, right panel). In contrast, the severity of EAO in C.D2-3.2a and C.D2-3.2b was not significantly different from that of CByJ mice. Moreover, dominant resistance co-segregated with Orch3 as evidenced by the fact that no significant difference in the PI between homozygous and heterozygous mice was detected across all congenic lines studied (Figure 2 and Figure 3). Taken...
Figure 2. Congenic mapping places Orch3 within the Kif1c/Nlrp1a/b/c interval. For convenience, D2 alleles have been shaded. The significance of differences in severity of EAO among CByJ, CD2F1 hybrids and CD2-ISRC lines was determined using the Kruskal-Wallis test (overall p-value < 0.0001) followed by Dunn’s multiple comparison test. Region outlined in blue depicts the location of Orch3.

doi:10.1371/journal.pgen.1003140.g002

Figure 3. Identification of Orch3 as Kif1c. (CD2-3.2 x CByJ) x CByJ backcross mice were screened from recombinants using microsatellite markers spanning the Orch3 interval. Three sub-ISRC lines were identified, fixed and homozygous progeny studied for susceptibility to EAO (D = D2 allele; C = CByJ allele). The significance of differences in EAO among CByJ, CD2-3.2a, CD2-3.2b, CD2-3.2c and Tg-Kif1cD2 transgenic mice was determined using the Kruskal-Wallis test (overall p-value < 0.0001) followed by Dunn’s multiple comparison test (**p < 0.01). Region outlined in red reflects location of Orch3 based on high resolution congeneric mapping relative to the lower resolution mapping outlined in blue.

doi:10.1371/journal.pgen.1003140.g003
together, these data restrict *Orh3* to a ~1.3 Mb interval distal of *D11Mit298* (69339966–69340164) and proximal of *D11De30* (70552627–70552762) which includes *Kif1c* but not *Nip1a* and *Nip1b* (Figure 3, left panel), thereby excluding them as positional candidates for *Orh3*.

Given the role of *Kif1c* in macrophage function [15], and that kinesins have been implicated in antigen processing and presentation [16], we decided to directly test the hypothesis that *Orh3* is *Kif1c*. We generated a transgenic mouse line that selectively expressed the resistant *Kif1cD2* allele on the susceptible CB6 background using the human CD11B/ITGAM regulatory elements for macrophage/myeloid-specific expression of *Kif1cD2* (Figure 4A). The expression of the transgene did not affect macrophage/myeloid cell generation or homeostasis as similar percentages of splenic F4/80+ cells (Figure 4B) and CD11b+ cells (Figure 4C) were detected on Tg-*Kif1cD2* mice compared to negative littermate control (NLC) mice. In addition, no differences in the expression of CD40 or CD86 were observed between strains at baseline (data not shown). Compared to NLC, greater Kif1c protein expression was seen in thioglycolate-induced Tg-*Kif1cD2* cells (Figure 4D). Despite the existence of polymorphisms upstream of *Kif1c* in potential regulatory regions [http://phenome.jax.org/], we did not observe differences in *Kif1c* expression at the mRNA level between the *Kif1cCB6* and *Kif1cD2* alleles (Figure 4E). NLC and Tg-*Kif1cD2* mice were studied for susceptibility to EAO. The expression of *Kif1cD2* in CD11b+ cells protected susceptible CB6 mice from developing EAO (Figure 3, right panel). This finding establishes *Kif1c* as being *Orh3*.

**Figure 4. Generation of BALB/cByJ-CD11B-Kif1cD2 transgenic (Tg-Kif1cD2) mice.** (A) Schematic representation of the *Kif1c* gene used to generate the transgenic mice showing the promoter (CD11B/ITGAM), and the *Kif1c* gene, followed by the hGH/polyA signal sequence. Arrows indicate PCR-primers for screening. (B and C) Percentage of splenic F4/80+ (B) and CD11b+ (C) cells of Tg-*Kif1cD2* and NLC. The analysis was performed on gated live cells according to their FSC vs. SSC profile. Statistical significance was determined using the Mann-Whitney test. Data represent the mean ± SEM of at least 5 individual mice. (D) Kif1c expression in thioglycolate-induced adherent cells by Western blotting using whole-cell extracts and the anti-Kif1c mAb. Actin was used as a loading marker. (E) mRNA expression of *Kif1c* was measured from sorted TCRβ+ CD19+ CD11b+ myeloid cells of CB6 mice and compared with TCRβ+ CD19+ CD11b- myeloid cells of D2 mice. [ß]-microglobulin and GAPDH were used as an endogenous control. Data represent the mean ± SEM of two experiments (pool of 5 animals/each).

doi:10.1371/journal.pgen.1003140.g004

Tg expression of *Kif1cD2* downregulates MHC class II expression and antigen presenting function of CD11b+ cells

To better understand the mechanism of resistance to EAO conferred by *Kif1cD2*, microarray analyses were performed on CD11b+ cells from NLC and Tg-*Kif1cD2* mice. Using a false discovery rate (FDR) cutoff of 0.05, we determined that 164 genes were differentially expressed between NLC and Tg-*Kif1cD2* CD11b+ cells (Table S1). An analysis for functional inference using Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com) revealed that T helper cell differentiation was the most significant pathway influenced by *Kif1c* (p<2.80 E-10; Figure S3 and Table S2). In addition, 18 of the top 20 pathways implicated a role for MHC class II, including antigen presentation. Indeed, compared to NLC CD11b+ cells, we observed a marked down regulation in MHC class II gene expression by Tg-*Kif1cD2* CD11b+ cells (Table S1 and Figure 5A, dark blue dots). This is consistent with the role of kinesin as the motor that drives MHC class II to the plus end of microtubules toward the cell surface [16].

To corroborate diminished class II expression, flow cytometric analysis was performed using naive TCRβ+CD19+CD11b+ splenocytes. The results presented in Figure 5B show lower MHC class II expression on Tg-*Kif1cD2* cells compared to NLC, D2, and C.D2-3.2 mice. Despite the differences in MHC class II expression, no significant difference in the proportion of total splenic CD11b+ cells was observed (Figure 4C). Therefore, expression of the transgene in CD11b+ cells negatively regulates MHC II protein levels.
To further establish a functional role for the differential expression of MHC class II, we assessed antigen presentation by examining Ag-specific T cell proliferation. NLC and Tg-Kif1cD2 mice were immunized with ovalbumin (OVA)+CFA or proteolipid protein (PLP) 190–199 peptide (PLP190-199)+CFA on d0 and d7. Spleen and lymph nodes (LN) were harvested at d10 and the proliferative responses evaluated. Compared to NLC antigen presenting cells (APCs), T cell proliferation in response to OVA was significantly reduced when T cells were stimulated in the presence of Tg-Kif1cD2 APCs (Figure 6A). Similar results were observed for PLP190-199-dependent T cell responses (Figure 6B). These data show that the Kif1cD2 allele in CD11b+ cells confers resistance to EAO by modulating APC function. Taken together our data suggest that Kif1c coding region polymorphism controls susceptibility to autoimmune orchitis.

Figure 5. Analysis of MHC II expression on splenic CD11b+ myeloid cells. (A) Scatterplot of genes differentially expressed in splenic TCRβ⁺ CD19⁺ CD11b⁺ myeloid cells of Tg-Kif1cD2 and NLC mice as determined by microarray. There were 164 genes differentially expressed (FDR<0.05) and for each gene, the log2 fold change was plotted on the ordinate against the -log10 p-value, plotted on the abscissa. Each data point represents the log2 fold change (Tg-Kif1cD2 minus NLC) for each gene. Dark blue data points indicate H2 genes that were downregulated in splenic CD11b+ cells of Tg-Kif1cD2 mice. (B) Flow cytometric analysis of the frequency of TCRβ⁺ CD19⁺ CD11b⁺ myeloid cells expressing MHC II in the spleen of Tg-Kif1cD2, D2, D2.C3.2, and NTC. Statistical significance was determined using the Kruskal-Wallis test (overall ***p-value<0.0001) followed by Dunn’s multiple comparison test (**p<0.01, *p<0.05). Data represent the mean ± SEM of at least 5 individual mice.

doi:10.1371/journal.pgen.1003140.g005

Amino acid polymorphisms at residues 578 and 1027 on the C-terminal end of Kif1c regulate its function

Kif1c alleles possess amino acid substitutions at residues 578, 1027, and 1066 [17]. Four haplotypes have been identified: LSS (Kif1cLSS), PSS, PPS, and PPY (Kif1cPPY). In addition, it has been shown that the C-terminal region of KIF1c is involved in protein-protein interactions and cargo function [17–20]. Therefore, substitutions at 578, 1027, and/or 1066 may have a significant impact on KIF1c function. Given that KIF17b has been shown to control CREM-dependent transcription by regulating the intracellular location of the transcriptional coactivator ACT (activator of CREM in testis) [21,22], and CREM binding to the Il2 promoter suppresses its activity [23], we evaluated the effect of LSS Kif1cLSS and PPY Kif1cPPY alleles on Il2 transcriptional activity as an in vitro assay of KIF1c allelic function. Jurkat cells were co-transfected with a plasmid containing the PPY Kif1cPPY allele, the LSS Kif1cLSS allele, or an empty plasmid, and an Il2-promoter luciferase reporter. Cells were then activated with phorbol myristate acetate (PMA) and calcimycin, a calcium ionophore, and the luciferase activity quantified. Jurkat cells that were transfected with the plasmid containing the PPY Kif1cPPY allele displayed significantly decreased luciferase activity (mean decrease 31.46±6.59%, P = 0.03) as compared to the control plasmid containing the LSS Kif1cLSS allele or the control plasmid (Figure 7A). These data demonstrate the functionality of the KIF1c structural polymorphism.

To further characterize the amino acid(s) responsible for the observed differences on Il2-promoter activity associated with the alleles, we replaced the D2-P578→L578 (LPY-KIF1c) or D2-P1027→P1027 (PSY-KIF1c) mutant alleles, with the wild type D2 allele or a control plasmid, and Il2-promoter luciferase reporter. Cells were activated with PMA and calcimycin and luciferase activity was assessed. As shown in Figure 7B, LPY-KIF1c and PSY-KIF1c mutants resulted in increased Il2-promoter luciferase activity compared to the D2 PPY-KIF1c allele. Taken together, our data demonstrate that structural polymorphisms at position 578 and 1027 are critical for KIF1c allelic functions.

Discussion

EAO is an organ-specific autoimmune disease that is a model of immunological male infertility [1,2]. We previously demonstrated
that genetic control of EAO is complex and involves both H2-linked (Orch1) and non-H2-linked (Orch3, Orch4, and Orch5) genes [24,25]. The H2-linked immune response genes primarily control susceptibility to EAO, whereas the non-H2-linked genes suppress the phenotypic expression of disease associated with a susceptible Orch1/H2 allele [9]. Here, we report the identification of Orch3 as Kif1c, which suppresses EAO by decreasing MHC class II expression and impairing APC function. Importantly, Kif1c may be a shared-autoimmune gene controlling susceptibility to experimental allergic encephalomyelitis (EAE) [26]. Eae7, Eae22, and Eae23 are linked to Orch3 [27], and CByJ and D2 mice are susceptible and resistant to EAE, respectively [28].

With the exception of tyrosine kinase-2 (Tyk2), in which a rare single nucleotide polymorphism in a well conserved APE motif within the pseudokinase domain is fully penetrant in controlling susceptibility to autoimmune diseases [29,30], the vast majority of non-MHC autoimmune loci identified to date are QTL that exhibit only partial to minimal penetrance. This has proven to be problematic as researchers have attempted to positionally clone and characterize such genes [31]. The fact that Orch3/Kif1c controls a dominant negative immunoregulatory mechanism that suppresses autoimmune orchitis with a high degree of penetrance is unique. Because EAO resistance is conferred in a dominant manner, we conclude that Kif1c alleles possess amino acid substitutions at residues 578 and 1027 [17]. Here, we demonstrated that residues 578 and 1027 are functionally significant. Although the amino acid polymorphism at residue 1027 is not in an evolutionarily conserved domain [17], it is in the C-terminal region believed to participate in cargo binding. In fact, alterations of this domain have been shown to modify in vivo kinesin protein function [19]. Moreover, it has been shown that the C-terminal tail domain of KIF1c (amino acids 811–1090) is involved in the interaction with bicaudal-D-related protein 1 (BDRP1) and this interaction regulates secretory transport required for neurite development [20]. Therefore, the ability of Kif1c to bind and transport cargo may be altered by polymorphism in this region. However, motor-dependent Golgi-to-ER transport functions normally in Kif1c knockout mice [44]. Immunohistochemical staining partially co-localized KIF1c with the Golgi marker CTR433, suggesting that KIF1c may also be involved in transport around the Golgi apparatus rather than only Golgi-to-ER transport. Accordingly, Wubbolts, et al. [16] showed that kinesin plays a role in the vesicular transport of MHC II-containing lysosomes from the microtubule organizing center region towards the cell surface. Here, we provide evidence that the resistant Kif1c allele negatively regulates the expression of MHC II proteins on APCs, since Tg-Kif1cCD11b+ cells express lower mRNA and protein levels. The reduction in MHC II expression by CD11b+ Tg-Kif1cCD11b+ cells was directly correlated with impaired antigen presentation as reflected by diminished Ag-specific T cell proliferative response. Whether amino acids at position 578 and 1027 on Kif1c are involved in MHC II expression is currently under investigation. Taken together, our results nevertheless provide mechanistic insight into how polymorphism in other kinesins including KIF21B and KIF5A influence human autoimmune disease susceptibility.

Materials and Methods

Ethics statement

Mice were housed at 25°C with 12/12-h light-dark cycles and 40–60% humidity. The experimental procedures performed in this study were under the guidelines of the Animal Care and Use Committees of the University of Vermont (Burlington, VT) and University of Illinois at Urbana-Champaign (Urbana, IL).

Animals

BALB/cByJ (CByJ), DBA/2J (D2), and (BALB/cByJ×DBA/2J)F1 hybrid (CD2F1) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The congenic lines in this study were generated using (BALB/cAnPt×DBA/2NCr)×BALB/cAnPt backcross mice [45]. Third generation backcross mice heterozygous at Eae2 or at Hba and Es3 were selected and backcrossed for six generations to BALB/cAnPt mice and fixed by brother-sister mating to generate the C.D2-Eae2 and C.D2-Hba/Ea3 lines. Overlapping interval specific recombinant congenic (ISRC) lines were generated by crossing CD2-Eae2 mice to CByJ mice. F2 hybrids were genotyped using tail snip DNA and PCR with Chr11 microsatellite markers discriminating CByJ and D2 mice across the Orch3 candidate interval. Founders were analyzed for background contamination at a density of 2–5 cM and mice
carrying CByJ alleles at all background marker loci were backcrossed an additional two generations to CByJ mice. The lines were fixed by brother-sister mating to generate the C.D2-3, C.D2-5, C.D2-8, and C.D2-9 ISRC lines. Similarly, higher order resolution mapping panels of ISRC lines were generated by screening (C.D2-3 × CByJ) × CByJ, (C.D2-5 × CByJ) × CByJ, and (C.D2-8 × CByJ) × CByJ backcross mice for recombinants. The genealogy and complete genotypes of the C.D2 congenic mice used in this study are given in Figure S1 and Figure S2, respectively.

The CByJ.CD11B-Kif1cD2 transgenic (Tg-Kif1cD2) mice were generated by microinjection with a construct containing the human CD11B/ITGAM promoter [46], Kif1cD2 cDNA, and the human growth hormone (hGH) polyA signal [47] into C57BL/6J fertilized eggs at the University of Vermont Transgenic/Knockout Facility. Mice were screened for hGH gene by PCR using hGH Fwd 5’ TAG GAA GCC TAT ATC CCA AAG G 3’ and hGH Rev 5’ ACA GTC TCT GCA AGT CAG TGG GG 3’ primers. Proinsulin Fwd 5’ CTA GGT GCA GTA GGT CTC CAG 3’ and proinsulin Rev 5’ CCT GCC TAT CCT TCA GGT C 3’ primers were used as internal control.

PCR-based restriction fragment length polymorphism (RFLP)

Genomic DNA was PCR-amplified using standard conditions and the following primers designed around a polymorphism in Nip1.1a: 5’-GGGCCCCAGATTTGAGATGt-3’; 5’-AGA-GACCCCAACCCACCTTCC-3’. 10 μl of PCR reaction was digested using 5 units of ApaLI in 50 μl of 1× NEBuffer 4 (New England BioLabs, Ipswich, MA) for 1 hour at 37°C. Resulting fragments were electrophoresed in 2% agarose gels and visualized by ethidium bromide.

EAO induction

Six- to 12 week old mice were immunized as previously described [9] with 10 mg of TH plus CFA (Sigma-Aldrich, St. Louis, MO) supplemented with 200 μg of Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit, MI) in conjunction with PTX (List Biological Laboratories Inc., Campbell, CA). EAO was evaluated at 25–30 days post-injection. The tests were processed for histological examination as previously described [9]. Histopathologic analysis was carried out in a double-blind manner with each test being scored individually on a PI from 0–10 as described previously [9]. The overall score for each animal was calculated as the average of both tests with the strain means representing the average of the averages.

Cell preparation and Western blotting

Spleens were collected from CByJ and Tg-Kif1cD2 mice, and single cell suspensions were prepared by passing the cells through a 50 μm nylon mesh (Small parts Inc, Miami Lakes, FL). Erythrocytes were lysed using complete Geyes solution, washed two times and plated to obtain adherent cells. Adherent cells were removed by treating with 0.025% Trypsin-EDTA (Invitrogen, Carlsbad, California), washed three times and pelleted. Whole-cell lysates were prepared in Triton lysis buffer and equal amounts of protein were then separated via SDS-PAGE and transferred to nitrocellulose membranes as described previously [48]. Primary antibodies used for Western blot include anti-Kif1c and anti-Actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Bound antibody was visualized by peroxidase-conjugated secondary antibody and detected by chemiluminescence (Kirkegaard and Perry Laboratories, Gaithersburg, MD).

FACS sorting and flow cytometric analysis

NLC and Tg-Kif1cD2 myeloid cells from erythrocyte-free spleens were first enriched by negative selection (using magnetic beads, Qiagen, Hilden, Germany) to deplete cells expressing CD8, CD4, and IgM. For FACS isolation, negatively selected enriched-myeloid cells were stained with anti-CD11b–APC-Cy7 (BD Pharmingen, Franklin Lakes, NJ), anti-CD11c–PE-C5.5 (Invitrogen, Camarillo, CA), anti-TCRβ–FITC, and anti-IA/IE–PE (eBioscience, San Diego, CA), and sorted on a FACSaria (BD Biosciences, San Jose, CA) by gating in the TCRβ–IA/IE–CD11c–CD11b+ myeloid cell population. Antibodies against B220 and CD19 (eBioscience) were also used for flow cytometry.

Microarray analysis

Total RNA was extracted and purified from TCRβ–IA/IE–CD11c–CD11b+ myeloid cells from naive NLC and Tg-Kif1cD2 mice (n=6 to 10 mice/strain) using RNeasy isolation reagent (Qiagen Inc.). Purified RNA was quantified using a Nanodrop ND1000 spectrophotometer (Thermo Scientific, Wilmington, DE) and quality was assessed using an Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, California). The RNA integrity number of all samples was greater than 8. For microarray analysis, two RNA pools were created so that each pool contained RNA from 3 to 5 mice, and two arrays per strain were analyzed.

RNA amplification and microarray analysis was performed at UVM Microarray Core Facility using previously described protocols [49]. Briefly, 2 μg of total RNA from each pooled sample were reverse transcribed to the single stranded cDNA using T7-oligo(dT) primer. T4 DNA polymerase was used to synthesize double-stranded cDNA, which served as a template for in vitro transcription using T7 RNA polymerase to produce biotinylated cRNA. The biotinylated cRNAs were fragmented into 30- to 200-base fragments and then hybridized to GeneChip Mouse Genome 430A 2.0 Arrays for 16 h at 45°C in a rotating Affymetrix GeneChip Hybridization Oven 320. After hybridization, arrays were washed and stained with streptavidin-phycoerythrin on an automated Affymetrix GeneChip Fluidic Station F450. The arrays were scanned with an Affymetrix GeneChip Scanner 2700 and the images quantified using Affymetrix GeneChip Operating Software.

The signal intensity for each probe on each chip was calculated from scanned images using GeneChip Operating Software (Affymetrix), and signal intensities were analyzed using BioConductor (http://www.bioconductor.org). Probe intensities were background corrected, normalized, and summarized using the Robust Multichip Average method described by Speed and coworkers [50,51]. An alternative normalization method based on reference genes did not significantly change the results. The FDR for differential expression between NLC and Tg-Kif1cD2 for each individual gene was calculated using the method of Benjamini and Hochberg [52]. Gene expression data were analyzed using a threshold of FDR≤0.05 to identify differentially expressed genes.

T cell stimulatory capacity of antigen presenting cells (APCs)

NLC and Tg-Kif1cD2 mice were immunized at d0 and d7 s.c. in the posterior right and left flank and the scruff of the neck with a sonicated PBS/oil emulsion containing 20 μg of OVA, faction V (Sigma-Aldrich, St. Louis, MO), or 100 μg of PLP180–199 in CFA supplemented with 200 μg of Mycobacterium tuberculosis H37Ra. Spleens and LN were harvested on d10. APCs from erythrocyte-free spleens were obtained by anti-CD4/anti-CD8 complement
depletion and treated with mitomycin C (25 μg/ml; Sigma-Aldrich). Responder CD4 T cells from LN and spleens were isolated by negative selection as previously described [40]. Single cell suspensions of OVA- or PLP180-199-APCs (2 × 10^6 cells/well) and Ag-specific responder CD4 T cells (1 × 10^6 cells/well) subcultures were transfecting a plasmid encoding kif1cPSY, Kif1cCByJ alleles, LPY-KIF1c and PSY-KIF1c mutants, corresponding empty vector (pcDNA, Invitrogen, Carlsbad, CA), luciferase reporter, and control pGL2 luciferase reporter (Promega, Madison, WI). The luminescence was measured immediately using a luminometer (Sunnyvale, CA). The transfec-
tion efficiency was compared between the samples by co-
transfecting a plasmid encoding Evi2 or and Hbaa/Es3 were fixed by brother-sister mating. Overlapping interval specific recombinant congenic [ISRC] lines were used for transfection of approximately 50 μg/ml of OVA or 2.5, 10, and 50 μg/ml of PLP180-199 for 72 h at 37°C. During the last 18 h of culture, 1 μCi of [3H] thymidine (PerkinElmer, Santa Clara, CA) was added. Cells were harvested onto glass fiber filters and thymidine uptake was determined with a liquid scintillation counter.

Preparation of Jurkat cells, transfection, stimulation, and luciferase assays
Jurkat cells were cultured in RPMI containing 10% FBS without stimulation for 24 hours at a concentration of 1 × 10^6 cells/ml. Plasmids encoding kif1cPSY, Kif1cCByJ alleles, LPY-KIF1c and PSY-KIF1c mutants, corresponding empty vector (pcDNA, Invitrogen, Carlsbad, CA), IL2 promoter (−575 to +57 base pairs) luciferase reporter, and control pGL2 luciferase reporter (Promega, Madison, WI) were used for transfection. Five micrograms of each plasmid were used for the transfection of approximately 5 × 10^6 Jurkat cells by electroporation at 250 mV and 900 μF in 250 μl of RPMII with a BioRad electroporator (BioRad, Hercules, CA). Cells were subsequently cultured in RPMI and 10% FBS for 24 hours and then stimulated with PMA (10 ng/ml) and calcium ionophore calcimycin (0.5 μg/ml) for 3 hours. Cell lysates were prepared and supernatants collected to quantify luciferase activity (Promega, Madison, WI). The luminescence was measured immediately using a luminometer (Sunnyvale, CA). The transfection efficiency was compared between the samples by cotransfecting a plasmid encoding β-galactosidase. The luciferase activity was normalized using the β-galactosidase value.

Mutagenesis
Point mutations were introduced in the plasmid encoding the Kif1c allele from the D2 mouse using the QuikChange Site-Directed mutagenesis kit (Stratagene, USA). Briefly the plasmid was denatured and then annealed with the appropriate mutagenic primer that contained the desired mutation. Using Pfu DNA polymerase, new mutagenized strands were created. The parental DNA template was digested with DpnI and the new mutated plasmid was used to transform E. coli. The plasmid DNA was extracted using the Qiagen Maxi-Prep kit (Qiagen, Valencia, CA). The primers used for mutagenesis of the nucleotide at position 1033 (amino acid 578) of the D2 allele were: forward: 5’-GCTCGTGACGAGCTCTGTCTGGTGTTGATGTC-3’; reverse: 5’-GACTTCCAGCCACCGACGCTCGTCGAGACG- 3’; and for the nucleotide at position 3079 (amino acid 1027):
Forward: 5’GGAAGACCCACCGGTTCCTCGACGCCAGATTCCC-3’, and Reverse: 5’GGGATTTCCCTGGAGAAGGGTGGTCTCGTCTG-3’.

Supporting Information
Figure S1 Genealogy of the congenic and interval specific congenic lines used in this study. Third backcross generation (BALB/cAnPt×DBA/2NCr)×BALB/cAnPt mice heterozygous at Evi2 or at Hbaa and Es3 were selected and backcrossed for six generations to BALB/cAnPt mice. Homozygous lines C.D2-Evi2 and C.D2-Hbaa/Es3 were fixed by brother-sister mating. Overlapping interval specific recombinant congenic [ISRC] lines were used for crossing C.D2-Evi2 mice to CByJ mice. F2 hybrids were genotyped using tail snip DNA and PCR with Chr11 microsatellite markers discriminating CByJ and D2 mice across the Orch3 candidate interval [10]. Founders were analyzed for background contamination and mice carrying CByJ alleles at all background marker loci were backcrossed an additional two generations to CByJ mice. Homozygous C.D2-3, C.D2-5, C.D2-8, and C.D2-9 ISRC lines were fixed by brother-sister mating. Similarly, higher order resolution mapping panels of ISRC lines were generated by screening (C.D2-3×CByJ)×CByJ, (C.D2-8×CByJ)×CByJ and (C.D2-3.2×CByJ)×CByJ backcross mice for recombinants.

PDF

Figure S2 Genotypes of congenic and interval specific congenic lines used in this study. Microsatellite and SNP based genotyping was done using tail snip DNA and PCR [10]. Locations are as given on either Ensembl or MGI. Hbaa alleles were determined by isoelectric focusing as described in [53]. Dナー marker and deletion mutation locations are as described in [54]. Evi2 and Es3 alleles were determined as described in [55].

PDF

Figure S3 Illustration of the potential effect of altered MHC Class II expression on T helper (TH) cell differentiation. (Figure generated using Ingenuity Pathway Analysis, Ingenuity Systems. Green = expression decreased in Tg-kif1cPSY relative to NLC).

Table S1 Genes differentially expressed between NLC and Tg-kif1cPSY CD11b+ cells. TCRβ IA/IE CD11c− CD11b+ myeloid cells were harvested from naive NLC and Tg-kif1cPSY mice and differential gene expression was detected using Affymetrix GeneChip Mouse Genome 430A 2.0 Arrays. Chr = chromosome.

PDF

Table S2 Transgenic expression of Kif1cPSY on CD11b+ cells influences pathways involving MHC Class II (genes in bold). TCRβ IA/IE CD11c− CD11b+ myeloid cells were harvested from naive NLC and Tg-kif1cPSY mice and differential gene expression was detected using Affymetrix GeneChip Mouse Genome 430A 2.0 Arrays. Pathway analysis was conducted using Ingenuity Pathway Analysis software (Ingenuity Systems, www.ingenuity.com). To ensure biological relevance, cell type was restricted to B-cells, dendritic cells, and macrophages.

PDF

Acknowledgments
We thank Dr. Christopher L. Berger for helpful discussion and Kevin Ladfision for the excellent technical support provided; Dr. Mercedes Rincon and John T. Dodge at the UVM Transgenic/Knockout Mouse Facility for assistance with the generation of Tg-kif1cPSY mice; T. Hunter, S. Tighe, Mary Lou Shane, and the staff at the UVM Advanced Genome Technologies Core for assistance with microarray and qRT-PCR; and Colette Charland for cell sorting.

Author Contributions
Conceived and designed the experiments: RdR RDM NDM GCT CT. Performed the experiments: RdR RDM NDM VCK. Analyzed the data: RdR EHW JPB KSKT VCK GCT CT. Wrote the paper: RdR EHW CT.
References


